Cancer Family
Female Reproductive System Adnexal Neoplasm
CI-CAN-00000180Explore in graph →
Non-malignant765 active trials5 approved drugs94 evidence items
- NCIt
- C212117
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000180Explore in graph →
Clinical trials
3,476 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07100288 | Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian Cancer(INFPELV) | recruiting | — | 200 | Complejo Hospitalario Universitario Insular Materno InfantilOTHER | 1 | Aug 3, 2025 |
| clinicaltrials |
| NCT07096583 | An Exploratory Study on NK Cell-assisted Prevention of Bone Marrow Suppression During Chemotherapy for Ovarian Cancer | active not recruiting | Phase 1 / Phase 2 | 20 | Anhui Provincial Cancer HospitalOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT07088588 | Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors | not yet recruiting | Phase 1 | 105 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05406674 | Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer(CisCon) | active not recruiting | Phase 2 | 40 | The Netherlands Cancer InstituteOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06666270 | Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 30 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07075250 | Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study(RIFOC003) | not yet recruiting | Phase 4 | 30 | Peking University People's HospitalOTHER | 0 | Jul 20, 2025 | clinicaltrials |
| NCT06019923 | Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer | recruiting | — | 100 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT07067255 | Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer(BAH2573-104) | recruiting | Phase 1 / Phase 2 | 80 | Essen BiotechOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07068178 | Evaluating the Efficacy of Hyperthermic Intraperitoneal Treatment to Enhance the Sensitivity of Immune Checkpoint Inhibitor in Patients With Advanced Ovarian Cancer： A Single-arm Study(ICI-HIPET) | not yet recruiting | Phase 2 | 30 | Jing LiOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07068464 | ICRA Randomised Controlled Trial(ICRA) | not yet recruiting | Phase 3 | 682 | NHS GrampianOTHER_GOV | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07069335 | A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer | recruiting | Phase 1 | 24 | Boryung Pharmaceutical Co., LtdINDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06839144 | Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression(OC-POP-PT) | recruiting | Phase 2 | 60 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jul 11, 2025 | clinicaltrials |
| NCT07059676 | Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer(LIBINI-1) | not yet recruiting | — | 120 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 0 | Jul 11, 2025 | clinicaltrials |
| NCT07058753 | Prehabilitation in Ovarian Cancer Patients During Chemiotherapy Before Cytoreductive Surgery.(PREHONED) | enrolling by invitation | N/A | 100 | Medical University of SilesiaOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT07022535 | Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer(PRESELECT-0) | recruiting | Phase 2 | 18 | The University of Hong KongOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07023484 | Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer(Preselect-1) | recruiting | Phase 2 | 126 | The University of Hong KongOTHER | 2 | Jul 2, 2025 | clinicaltrials |
| NCT07039331 | Short-term Fasting Compared to Free Diet on Ovarian Cancer Patients(DIETA) | recruiting | N/A | 54 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT07044349 | Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | not yet recruiting | Phase 2 | 72 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Jun 30, 2025 | clinicaltrials |
| NCT05796973 | Measuring Oncological Value of Exercise and Statin(MOVES) | recruiting | Phase 3 | 240 | Tampere University HospitalOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06602063 | Surgery for Relapsed Ovarian Cancer in Precision | not yet recruiting | Phase 1 / Phase 2 | 33 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06817174 | Ovarian Cancer Radiomics Approach in CT Led Evaluation(ORACLE) | recruiting | — | 168 | Imperial College Healthcare NHS TrustOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06139783 | Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors | not yet recruiting | N/A | 32 | Oncare MadridOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07035587 | Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques | recruiting | — | 1,200 | Yonsei UniversityOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT03522246 | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy(ATHENA) | active not recruiting | Phase 3 | 1,097 | pharmaand GmbHINDUSTRY | 24 | Jun 24, 2025 | clinicaltrials |
| NCT06769425 | HS-10502 Combination Treatment in Patients With Advanced Solid Tumors(HS-10502) | recruiting | Phase 1 | 157 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06954584 | Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer | recruiting | Phase 3 | 424 | Tongji HospitalOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06977594 | Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer | not yet recruiting | N/A | 1,000 | Seoul National University HospitalOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07031908 | Minimally Invasive Interval Debulking Surgery in Advanced Ovarian Cancer(MISSION-2) | not yet recruiting | — | 40 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT07028229 | Ultrasound Training Program for Gynecologic Cancer Staging in Residents(Ultra-teaching) | not yet recruiting | N/A | 6 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT02288676 | DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics(DOvEEgene) | recruiting | — | 1,200 | McGill UniversityOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT04024878 | NeoVax With Nivolumab in Patients With Ovarian Cancer | active not recruiting | Phase 1 | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT06564428 | A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration | recruiting | — | 1,000 | Peking University Third HospitalOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT06292286 | Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer(SCENIC) | recruiting | N/A | 18 | The University of Hong KongOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT01953159 | Assessment of Paclitaxel-Induced Neuropathy | active not recruiting | — | 43 | University of ChicagoOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT07009743 | O-RADS MRI System on Early Detection of Ovarian Cancer | active not recruiting | — | 2,549 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 8, 2025 | clinicaltrials |
| NCT05740956 | A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 318 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT05518253 | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 30 | Weijia Fang, MDOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06990503 | SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer | not yet recruiting | Phase 3 | 300 | Tongji HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06990516 | SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer | not yet recruiting | Phase 1 / Phase 2 | 90 | Tongji HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT02571725 | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | active not recruiting | Phase 1 / Phase 2 | 50 | New Mexico Cancer Research AllianceOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT04575961 | Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer(PERCEPTION) | active not recruiting | Phase 2 | 33 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06988280 | Ultrasound-guided Transvaginal Aspiration of Cystic Pelvic Lesions(UTAC) | recruiting | — | 100 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06129968 | Transforming Ovarian Cancer Diagnostic Pathways(SONATA) | recruiting | — | 34,000 | Professor Sudha SundarOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT05156892 | Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer(TICTOC) | active not recruiting | Phase 1 | 44 | Anthony Joshua, FRACPOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06972693 | NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma(PERSONA-Ovary) | active not recruiting | Phase 4 | 323 | European Institute of OncologyOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06973421 | Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 35 | Fudan UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT05179824 | Tempus Priority Study: A Pan-tumor Observational Study | active not recruiting | — | 1,000 | Tempus AIINDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT04503265 | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 122 | AtlasMedx, IncorporatedINDUSTRY | 1 | May 1, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 11, 2025source: clinicaltrials